Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors while in the central nervous technique, conolidine modulates alternate molecular targets. A Science Developments study located that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://roselynel864mor5.newsbloger.com/profile